LYKA LABS
Lyka Labs Share Price
Lyka Labs Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Lyka Labs Investment Rating
-
Master Rating:
-
Lyka Labs has an operating revenue of Rs. 172.14 Cr. on a trailing 12-month basis. An annual revenue growth of 123% is outstanding, Pre-tax margin of 31% is great, ROE of 292% is exceptional. The company has a high debt to equity of 463%, which can be a reason to worry. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 8 which is a FAIR score but needs to improve its earnings, a RS Rating of 43 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C which is evident from recent supply seen, Group Rank of 106 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has remained stable in the last reported quarter. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
- Indicator
- Jun 2022
- Mar 2022
- Dec 2021
- Sep 2021
- Jun 2021
- Mar 2021
- Oper Rev Qtr Cr
- 22
- 28
- 28
- 65
- 43
- 18
- Operating Expenses Qtr Cr
- 16
- 16
- 16
- 21
- 14
- 12
- Operating Profit Qtr Cr
- 6
- 12
- 12
- 44
- 30
- 5
- Depreciation Qtr Cr
- 3
- 9
- 2
- 2
- 2
- 2
- Interest Qtr Cr
- 3
- 3
- 5
- 6
- 7
- 6
- Tax Qtr Cr
- 0
- 13
- 0
- 6
- 2
- -4
- Net Profit Qtr Cr
- 0
- -15
- 6
- 30
- 20
- 0
Lyka Labs Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 0
- Bearish Moving Average
- ___
- 16
- 20 Day
- 123.06
- 50 Day
- 125.97
- 100 Day
- 134.4
- 200 Day
- 152.73
- 20 Day
- 125.52
- 50 Day
- 122.69
- 100 Day
- 135.94
- 200 Day
- 153.21
Lyka Labs Resistance and Support
- First Resistance
- 121.44
- Second Resistance
- 125.02
- Third Resistance
- 127.49
- First Resistance
- 115.39
- Second Resistance
- 112.92
- Third Resistance
- 109.34
- RSI
- 40.53
- MFI
- 52.83
- MACD Single Line
- -0.61
- MACD
- -2.21
Lyka Labs Delivery and Volume
- Period
- NSE + BSE
Volume Avg - NSE + BSE
Delivery Volume Avg - NSE + BSE
Delivery Volume %
- Day
- 62,898
- 4,014,779
- 63.83
- Week
- 70,528
- 4,359,336
- 61.81
- 1 Month
- 127,752
- 7,492,631
- 58.65
- 6 Month
- 148,556
- 9,439,279
- 63.54
Lyka Labs Result Highlights
Lyka Labs Synopsis
NSE-Medical-Generic Drugs
Lyka Labs is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 164.35 Cr. and Equity Capital is Rs. 28.69 Cr. for the Year ended 31/03/2022. Lyka Labs Ltd. is a Public Limited Listed company incorporated on 29/12/1976 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24230GJ1976PLC008738 and registration number is 008738.- Market Cap
- 334
- Sales
- 143
- Shares in Float
- 1.49
- No of funds
- 19
- Yield
- Book Value
- 7.5
- U/D Vol ratio
- 1.3
- LTDebt / Equity
- 137
- Alpha
- 0.23
- Beta
- 0.65
Lyka Labs
- Owner Name
- Jun-22
- Mar-22
- Dec-21
- Sep-21
- Promoters
- 47.8%
- 47.79%
- 20.04%
- Mutual Funds
- 3.54%
- 0.73%
- 0.01%
- Insurance Companies
- 0.46%
- 0.46%
- 0.46%
- Foreign Portfolio Investors
- 0.76%
- 1.12%
- 1.13%
- Financial Institutions/ Banks
- Individual Investors
- 38.85%
- 37.26%
- 33.34%
- Others
- 8.59%
- 12.64%
- 45.02%
Lyka Labs Management
- Name
- Designation
- Mr. Kunal N Gandhi
- Chairman & M.D & CEO
- Mr. Yogesh B Shah
- Executive Director & CFO
- Mrs. Nehal N Gandhi
- Non Executive Director
- Mr. Vinod S Shanbhag
- Independent Director
- Mr. Sandeep P Parikh
- Independent Director
- Mrs. Dhara P Shah
- Independent Director
Lyka Labs Forecast
Price Estimates
Lyka Labs Corporate Action
- Date
- Purpose
- Remarks
- 2022-08-08
- Quarterly Results & Amalgamation
- 2022-05-20
- Audited Results
- 2022-01-20
- Quarterly Results
- 2021-10-29
- Quarterly Results
- 2021-08-04
- Quarterly Results
Lyka Labs FAQs
What is Share Price of Lyka Labs ?
Lyka Labs share price is ₹116 As on 20 August, 2022 | 10:37
What is the Market Cap of Lyka Labs ?
The Market Cap of Lyka Labs is ₹333.5 Cr As on 20 August, 2022 | 10:37
What is the P/E ratio of Lyka Labs ?
The P/E ratio of Lyka Labs is 16.6 As on 20 August, 2022 | 10:37
What is the PB ratio of Lyka Labs ?
The PB ratio of Lyka Labs is 24.7 As on 20 August, 2022 | 10:37